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Clinical Efficacy
Primary Outcome
Esophageal eosinophil 
count: P < .0001 for 
both dose groups
Key Secondary Outcome
Dysphagia clinical 
symptom frequency
and severity (DSD): 
Not statistically significant 
for both dose groups
Safety Assessment
AEs 
All low frequency
Headache 
Upper respiratory tract 
infection
Arthralgia
Nasopharyngitis
Diarrhea
Nausea
SAEs
All unrelated to treatment 
RPC4046 180 mg or 360 mg 
treatment for 16 weeks See editorial on page 545.
BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is a
chronic, esophageal, type 2 inﬂammatory response associated
with increased serum levels of interleukin 13 (IL13), which
might contribute to its pathogenesis. RPC4046, a recombinant
humanized monoclonal antibody against IL13, prevents its
binding to the receptor subunits IL13RA1 and IL13RA2. We
performed a phase 2 trial to evaluate the efﬁcacy and safety of
RPC4046 in patients with EoE. METHODS: We performed a
multicenter, double-blind trial of 99 adults with active EoE
randomly assigned (1:1:1) to groups given RPC4046 (180 or
360 mg) or placebo once weekly for 16 weeks, from September
2014 through December 2015. Patients were seen at day 1
(baseline) and weeks 2, 4, 8, 12, and 16. They underwent
esophagogastroduodenoscopy and biopsies were collected atbaseline and week 16. Patients completed a daily dysphagia
symptom diary through week 16 and patient-reported outcome
data were collected. The primary outcome was change in mean
esophageal eosinophil count in the 5 high-power ﬁelds (hpfs)
with the highest level of inﬂammation. RESULTS: At week 16,
mean changes in esophageal eosinophil count per hpf were a
reduction of 94.8 ± 67.3 in patients who received 180 mg
RPC4046 (P < .0001) and a reduction of 99.9 ± 79.5 in patients
who received 360 mg RPC4046 (P < .0001) compared with a
reduction of 4.4 ± 59.9 in patients who received placebo. The
360-mg RPC4046 group, compared with the placebo group,
showed signiﬁcant reductions in validated endoscopic severity
score at all esophageal locations (P < .0001), validated histo-
logic grade and stage scores (both P < .0001), and clinician’s
global assessment of disease severity (P ¼ .0352); they had a
numerical reduction in scores from the dysphagia symptom
diary (P ¼ .0733). Signiﬁcant reductions in esophageal
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Eosinophilic esophagitis (EoE) is associated with elevated
interleukin 13 (IL13), which may have a central role in
disease pathogenesis. RPC4046, a recombinant
humanized monoclonal antibody against IL13, prevents
binding to both IL13 receptor subunits.
February 2019 RPC4046 EoE Phase 2 Trial 593eosinophil counts and histologic and endoscopic features were
observed in patients with steroid-refractory EoE who received
RPC4046. The most common adverse events were headache
and upper respiratory tract infection. CONCLUSIONS: In a
phase 2 trial of patients with EoE, we found RPC4046 (a
monoclonal antibody against IL13) to reduce histologic and
endoscopic features compared with placebo. RPC4046 was well
tolerated. ClinicalTrials.gov no: NCT02098473.NEW FINDINGS
This phase 2 trial provides evidence of the efﬁcacy and
safety of antibody against IL13 therapy with RPC4046 in
adult patients with EoE, with improvement in
histopathologic and endoscopic aspects of disease
activity and global perception of disease severity.
LIMITATIONS
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Immune Response.
osinophilic esophagitis (EoE) is a chronic, allergic/The study was not powered to assess dysphagia
symptom improvement. Furthermore, a validated
patient-reported outcome measure for EoE symptoms
was not available at the time the study was designed.
IMPACT
The data from this phase 2 trial substantiate the potential
contribution of IL13 in the pathogenesis of EoE and
support the further study of RPC4046 as a novel,
targeted approach for EoE.
Abbreviations used in this paper: DSD, dysphagia symptom diary; EEsAI,
eosinophilic esophagitis activity index; EoE, eosinophilic esophagitis;
EoEHSS, Eosinophil Histologic Scoring System; eos, eosinophil count;
EREFS, EoE endoscopic reference score; hpf, high-power ﬁeld; IL13,
interleukin 13; IV, intravenous; PRO, patient-reported outcome; SC,
subcutaneous.
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https://doi.org/10.1053/j.gastro.2018.10.051Eimmune-mediated clinicopathologic disease of the
esophagus characterized histologically by eosinophil-
predominant mucosal inﬂammation and clinically by signs
and symptoms of esophageal dysfunction.1,2 The prevalence
of EoE has increased dramatically since the original
description in 1993, with estimates of 0.5 to 1 cases per
1000 persons worldwide.3 Complications of EoE, including
strictures and food impaction, are related to esophageal
remodeling and ﬁbrostenosis, which are associated with a
longer duration of untreated disease.4,5 Presently, no ther-
apies are approved for EoE in the United States, although
an orodispersible budesonide tablet has recently been
approved in Europe. Current management approaches
include diet interventions designed to eliminate foods that
trigger the inﬂammatory response and topically acting glu-
cocorticosteroids that are swallowed to coat the esophageal
mucosa. Although these therapies are effective in reducing
eosinophilic inﬂammation, a signiﬁcant proportion of
patients are refractory, and the disease universally ﬂares
on weaning of therapy.6,7 Furthermore, reduction in
remodeling-associated alterations of the esophagus using
steroids has been incomplete, necessitating use of esopha-
geal dilation for strictures.8
Increased serum levels of interleukin 13 (IL13) might
contribute to the pathogenesis of EoE. Preclinical in vitro
modeling and human data have shown that IL13 is
overexpressed in the esophageal mucosa of patients with
EoE, induces a gene transcript proﬁle that overlaps with the
EoE-speciﬁc esophageal transcriptome,9 and modulates
cellular and molecular pathways involved in eosinophil
recruitment,10 esophageal barrier function,11 and tissue
remodeling and ﬁbrosis.12 Transgenic overexpression of
IL13 in mice induces marked esophageal eosinophilia,
extensive tissue remodeling, and an esophageal tran-
scriptome that overlaps with the EoE transcriptome seen in
patients.12 IL13 also markedly induces the gene product
encoded by the EoE major genetic susceptibility locus
(2p23), calpain-14, which modiﬁes esophageal epithelial
barrier.13,14 Furthermore, a small preliminary study using a
monoclonal antibody against IL13 demonstrated reductions
in esophageal eosinophil counts and EoE-related gene
expression.15 RPC4046 is a selective, high-afﬁnity, human-
ized immunoglobulin G1 monoclonal antibody that recog-
nizes wild-type and variant human IL13, and blocks itsbinding to the receptor subunits IL13Ra1 and IL13Ra2.16
We evaluated the efﬁcacy and safety of RPC4046 in adult
patients with clinically and histologically active EoE.
Methods
Trial Design
The double-blind period of this phase 2, randomized,
placebo-controlled trial was conducted at 30 centers in 3
countries (Supplementary Table 1) from September 2014 to
December 2015, with completion of the study marked by the
last safety follow-up in February 2016. The protocol and
amendments were approved by the institutional review board
or ethics committee at each center. All patients gave written
informed consent. See the Supplementary Materials for details
regarding site information, study administration, and protocol
amendments.
Patient Population
Eligible patients were 18 to 65 years of age with a
conﬁrmed diagnosis of EoE. Patients were required to have
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ATsymptoms of dysphagia for a minimum of 4 days over 2 weeks
(within the 4-week screening period) and histologic evidence of
EoE, deﬁned as a peak count of 15 eosinophils per high-
power ﬁeld (eos/hpf; microscope hpf ¼ 0.3 mm2) at any 2 of
3 levels of the esophagus (proximal, mid, distal) when off anti-
inﬂammatory therapy for EoE. Patients must have previously
received an adequate trial of a proton pump inhibitor to
exclude gastroesophageal reﬂux disease and proton pump
inhibitor‒responsive esophageal eosinophilia as the primary
cause of their symptoms. Prior treatment of patients with ste-
roids for EoE was recorded, with steroid refractory deﬁned as
an adequate trial of systemic or swallowed topical steroids
failing to result in a meaningful reduction in symptoms, as
judged by the investigator. Key exclusion criteria were pres-
ence of generalized eosinophilic gastroenteritis, active Heli-
cobacter pylori gastritis, Barrett’s esophagus, severe esophageal
stricture preventing passage of a standard adult diagnostic
upper endoscope, and esophageal dilation within 4 months of
screening. See the Supplementary Material for additional
inclusion and exclusion criteria.Randomization and Masking
The trial included a 16-week, double-blind treatment period
and an optional open-label period (Figure 1). This report
describes the double-blind treatment period. Patients were
randomly assigned (1:1:1) to groups given low-dose RPC4046
(5 mg/kg intravenous [IV] loading dose þ 180 mg subcutane-
ously [SC]) on day 1, then 180 mg SC once weekly for 15
additional weeks, or matching placebo (IV loading dose þ SC)
on day 1, then SC dose once weekly for 15 additional weeks, or
high-dose RPC4046 (10 mg/kg IV loading dose þ 360 mg SC)
on day 1, then 360 mg SC once weekly for 15 additional weeks
(Supplementary Material). Randomization was done centrally
on day 1 through an interactive voice response system/
interactive Web-based response system using a computer-
generated sequence that was programmed by anFigure 1. Studindependent, unmasked, statistical team at the contract
research organization. Randomization allocation was stratiﬁed
based on steroid-refractory status. The study drug, RPC4046,
and placebo solutions were identical in physical appearance.
The treatment each patient received was not disclosed to the
investigator, trial center personnel, patient, sponsor, or their
representatives. Each patient’s treatment group assignment
blind was not broken until all patients completed the double-
blind treatment period.Procedures
Patients were seen at day 1 (baseline) and weeks 2, 4, 8, 12,
and 16 during the double-blind treatment period. They
underwent esophagogastroduodenoscopy and biopsies were
collected at baseline and week 16 for esophageal eosinophil
count and additional histopathologic assessment. Patients
completed a daily dysphagia symptom diary (DSD) for at least
the last 2 consecutive weeks during the 4-week screening
period and daily from day 1 through week 16 (Supplementary
Materials). Other patient-reported outcome (PRO) data were
collected from the validated eosinophilic esophagitis activity
index (EEsAI),17 patient’s global assessment of disease severity,
and patient’s global impression of change in EoE symptoms
(Supplementary Material). Esophageal mucosal appearance was
determined at the time of each endoscopic examination by the
EoE endoscopic reference score (EREFS), a validated instru-
ment for assessing the presence and severity of the major
endoscopic signs of EoE, including esophageal edema, rings,
exudates, furrows, and stricture (Supplementary Material).18 A
central pathologist blinded to treatment allocation determined
EoE histologic changes. Mean (deﬁned later in this article)
esophageal eos/hpf and other parameters were assessed using
the EoE histology scoring system, a validated measure for
evaluating eosinophil density, basal zone hyperplasia, eosino-
phil abscesses, eosinophil surface layering, dilated intercellular
spaces, surface epithelial alteration, dyskeratotic epithelialy schematic.
Figure 2. Patient disposi-
tion and treatment through
week 16. aLightheaded-
ness. bFlu-like symptoms;
worsening EoE symp-
toms; pruritus and rash.
cBased on number of pa-
tients randomized.
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Material).19,20 Adverse events and concomitant medication
use were recorded through 16 weeks (24 weeks for patients
who did not continue into the open-label extension). Blood
samples were obtained at each clinic visit for clinical chemistry
and hematology, serum RPC4046 assessment, and serum anti-
bodies to RPC4046.
The primary efﬁcacy outcome was change in mean esoph-
ageal eosinophil count in the 5 hpfs with the highest level of
inﬂammation in the esophageal biopsies. The key secondary
efﬁcacy outcome was mean change in the dysphagia clinical
symptom frequency and severity from baseline to week 16 as
assessed by DSD completed over 2 weeks before the week 16
endpoint. Other secondary outcomes included change in EEsAI
PRO score, peak esophageal eosinophil count, EREFS, patient’s
and clinician’s global assessments of disease severity, patient’s
global impression of change in EoE symptoms, and esophageal
histologic severity (grade) and extent (stage).
Statistical Analysis
The trial was powered to determine the efﬁcacy of 180 mg
and 360 mg RPC4046 for the treatment of patients with EoE.
The planned sample size of 90 randomized patients (30 pa-
tients/arm) was justiﬁed based on previous published trials ofother therapies for EoE. The baseline mean eosinophil count
was expected to be in the range of 80 to 110 eos/hpf, with an
estimated standard deviation of change from baseline in
eosinophil counts of 30 to 50 eos/hpf. Using a 2-sided test at
the a ¼ .05 level of signiﬁcance and a conservative standard
deviation assumption of 50 eos/hpf, a sample size of 30 pa-
tients per arm provided 87% power to detect a treatment
difference of 40 eos/hpf and 93% power to detect a treatment
difference of 45 eos/hpf.
The trial had a parallel-group design; primary statistical
analyses were performed using analysis of covariance with
baseline mean esophageal eosinophil count measured in the 5
hpfs with the highest level of inﬂammation included as a
covariate and treatment group and steroid-refractory status
included as factors.
Comparisons between treatments and placebo were per-
formed at 2-sided a ¼ 0.05. All efﬁcacy analyses were
performed using the intention-to-treat principle. The primary
efﬁcacy outcome was change in mean esophageal eosinophil
count in the 5 hpfs with the highest level of inﬂammation at
week 16. A Cochran-Mantel-Haenszel c2 test was performed at
week 16 to compare the peak esophageal eosinophil count
response (<15 vs 15) by treatment group, controlling for
steroid-refractory status.
Table 1.Patient Demographics and Disease Characteristics
Placebo (n ¼ 34)
RPC4046
180 mg (n ¼ 31) 360 mg (n ¼ 34)
Age, y
Mean 38.6 ± 11.03 39.1 ± 9.87 33.9 ± 10.92
Median 38.5 40.0 31.5
Minimum, maximum 19, 64 19, 59 18, 63
Sex, n (%)
Male 22 (64.7) 19 (61.3) 20 (58.8)
Female 12 (35.3) 12 (38.7) 14 (41.2)
Race, n (%)
White 34 (100) 30 (96.8) 34 (100)
Black or African American 0 1 (3.2) 0
Years since EoE diagnosis, mean 4.26 ± 2.90 4.25 ± 3.82 3.92 ± 2.73
Steroid refractory, n (%) 16 (47.1) 14 (45.2) 16 (47.1)
Peak eosinophil count/hpf
Mean 105.4 ± 60.42 131.9 ± 84.55 139.4 ± 79.94
Minimum, maximum 18, 212 24, 304 26, 389
Eosinophil count/hpf
Mean 92.41 ± 54.11 116.65 ± 77.32 122.55 ± 71.08
Minimum, maximum 17.6, 189.8 21.4, 273.0 22.2, 369.2
Peripheral eosinophil count, 109/L
Mean 0.44 ± 0.23 0.51 ± 0.28 0.39 ± 0.19
Minimum, maximum 0.1, 1.0 0.1, 1.4 0.1, 0.8
Total IgE, IU/mL
Mean 96.2 ± 97.09 262.8 ± 289.60 190 ± 408.05
Minimum, maximum 1, 411 4, 1105 2, 2094
Daily symptom diary score
Mean 29.44 ± 10.70 27.63 ± 13.18 29.03 ± 10.13
Minimum, maximum 11.0, 51.0 6.6, 52.0 11.0, 49.0
EEsAI PRO score (range 0‒100)
Mean 56.1 ± 13.19 58.1 ± 12.22 56.2 ± 13.21
Minimum, maximum 34, 94 27, 92 34, 94
EoE EREFS features, n (%)
Edema 20 (62.5) 18 (66.7) 26 (78.8)
Rings 28 (87.5) 23 (85.2) 25 (75.8)
Exudates 16 (50.0) 21 (77.8) 20 (60.6)
Furrows 27 (84.4) 22 (81.5) 31 (93.9)
Stricture 13 (40.6) 9 (33.3) 9 (27.3)
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prespeciﬁed subgroup analyses, exploratory analyses, sensi-
tivity analyses, multiple post hoc subgroup analyses, and
approaches to handling missing data, are provided in the
Supplementary Material.
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.
Results
Baseline Patient Characteristics
Of the total 100 patients randomly assigned to study
groups, 99 patients received study drug or placebo
(Figure 2). One patient in the 180 mg RPC4046 group was
randomized in error, did not receive study drug, and
was excluded from the analysis. Patient demographics
were typical for an adult population with EoE, with
male predominance and median age between 30 and 40
years. Study groups were generally balanced with respectto demographic characteristics, except for slightly
younger patients in the 360 mg RPC4046 group and
higher baseline mean esophageal eosinophil count in the
180 mg (116.65 ± 77.32 eos/hpf) and 360 mg (122.55 ±
71.08 eos/hpf) groups compared with placebo (92.41 ±
54.11 eos/hpf) (Table 1, Supplementary Table 2). Ninety
of the 99 patients (90.9%) completed the 16-week treat-
ment period.Clinical Efﬁcacy
At week 16, mean reductions from baseline in esopha-
geal eosinophil count were 4.42 ± 59.94, 94.76 ± 67.27, and
99.90 ± 79.53 eos/hpf in the placebo, 180 mg RPC4046, and
360 mg RPC4046 groups, respectively. Mean changes
between either RPC4046 dose and placebo were statistically
signiﬁcant at week 16 (P < .0001 for both comparisons;
mean counts, Figure 3A). Peak esophageal eosinophil counts
were signiﬁcantly reduced, with 50% of patients treated
Figure 3. Clinical results for the overall EoE patient group include the following: the mean esophageal eosinophil count (eos/
hpf) at baseline and week 16 (primary endpoint) (A); peak esophageal eosinophil count (eos/hpf) at baseline and week 16 (B);
proportion of patients achieving peak esophageal eosinophil count <6 eos/hpf and <15 eos/hpf at baseline and week 16 (C);
mean change over the 14 days preceding each study visit in dysphagia symptom diary (DSD) score (± standard error) at
baseline and weeks 4, 8, 12, and 16 (P ¼ .0733 for 360 mg at week 16; daily DSD score range: 0‒6, with higher scores
indicating more severe dysphagia symptoms) (D); mean total EREFS at baseline and week 16 (endoscopic ﬁndings analyzed
according to modiﬁed scoring system described by Hirano et al 201318; total EREFS score range: 0‒8 for each location [ie,
total score range across 3 locations: 0‒24]) (E); and mean changes from baseline to week 16 in eosinophilic histology grade
(range: 0‒3 for each of 8 features for proximal and distal biopsies [ie, total score range: 0‒48]) and stage (range: same as for
grade) scores (F).
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Figure 4. For overall EoE patient group, mean patient’s global assessment of disease severity was signiﬁcantly reduced at
week 16 for the 360-mg RPC4046 group compared with placebo; P values from an analysis of covariance model were
adjusted for steroid-refractory status and baseline global assessment of disease severity score (A). Mean clinician’s global
assessment of disease severity was signiﬁcantly reduced at week 16 for the 180-mg and 360-mg RPC4046 groups compared
with placebo; P values from an analysis of covariance model were adjusted for steroid-refractory status and baseline global
assessment of disease severity score (B). Categorical analysis of the patient’s global impression of change from baseline in
EoE symptoms at week 16; P values comparing 180 mg RPC4046 with placebo and 360 mg RPC4046 with placebo were
based on the Wilcoxon rank-sum test (C). Mean change in the EEsAI score (± standard error) at weeks 4, 8, 12, and 16
(P ¼ .1103 for 360 mg at week 16) (D).
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compared with 0% placebo (P < .0001 for both compari-
sons), and 25% of patients in the 180 mg RPC4046 group
and 20% in the 360 mg RPC4046 group having <6 peak
eos/hpf after treatment (P ¼ .0027 and P ¼ .0079, respec-
tively) (Figure 3B and C).
Mean reductions in the EREFS total score of 1.2 ± 1.18
and 1.3 ± 1.22 between either RPC4046 dose (180 mg,
n ¼ 24; 360 mg, n ¼ 29) and placebo (n ¼ 31) were
statistically signiﬁcant over all esophageal locations at
week 16 (180 mg, P ¼ .0004; 360 mg, P < .0001) (mean
total scores, Figure 3E, Supplementary Table 3; stricture
features, Supplementary Table 4). Reductions in
mean adjusted Eosinophil Histologic Scoring System
(EoEHSS) grade scores of 26.651 ± 14.737 and 30.737 ±15.520 and stage scores of 22.853 ± 11.445 and 27.378 ±
13.198 between either RPC4046 dose (180 mg, n ¼ 28;
360 mg, n ¼ 30) and placebo (n ¼ 33) were statistically
signiﬁcant at week 16 (P < .0001 for both comparisons)
(Figure 3F).
Mean reductions in the patient’s global assessment of
disease severity score of 2.01 ± 1.68 and 2.8 ± 2.71
were signiﬁcant at week 16 with the 360-mg dose (n ¼ 27,
P ¼ .0107) but not with the 180-mg dose (n ¼ 30,
P ¼ .1035) (Figure 4A). Mean reductions in the clinician’s
global assessment of disease severity score of 3.6 ± 2.71
and 2.9 ± 2.70 were signiﬁcant at week 16 with the 180-
mg (n ¼ 27, P ¼ .0094) and 360-mg doses (n ¼ 30,
P ¼ .0352) (Figure 4B). Categorical analysis of patient’s
global impression of change in EoE symptoms at week 16
February 2019 RPC4046 EoE Phase 2 Trial 599did not show signiﬁcant improvements in either RPC4046
group (180 mg: n ¼ 31, P ¼ .4094; 360 mg: n ¼ 34,
P ¼ .0143) (Figure 4C).
At week 16, mean reduction in the DSD composite score
was greater in the 360-mg RPC4046 group compared with
the placebo group (13.31 ± 15.26 vs 6.41 ± 15.40), although
this was not statistically signiﬁcant (P ¼ .0733) (Figure 3D).
Patients receiving 360 mg RPC4046 showed a trend toward
greater reduction in the EEsAI PRO score vs placebo
(P ¼ .1103) (Figure 4D).CL
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In the prespeciﬁed subgroup of steroid-refractory
patients (n ¼ 47; Supplementary Table 2), mean re-
ductions in esophageal eosinophil count of 103.53 ± 89.166
and 130.12 ± 73.993 between 180 mg (n ¼ 14) and placebo
as well as 360 mg (n ¼ 17) and placebo (n ¼ 16)
were observed at week 16 (180 mg, P ¼ .0001; 360 mg,
P  .0001) (Figure 5A, Supplementary Table 5; steroid-
responsive subgroup, Supplementary Table 6). DSD com-
posite scores for the 360-mg RPC4046 group approached
signiﬁcance (P ¼ .054); however, this trend was not
observed for the 180-mg RPC4046 group (Figure 5B;
Supplementary Table 7; steroid-responsive subgroup,
Supplementary Table 6). Mean reductions in the EREFS
total score of 4.1 ± 4.21 and 4.2 ± 3.68 over all measured
locations at week 16 were reported in the 180-mg and
360-mg RPC4046 groups, respectively (180 mg, P ¼ .0026;
360 mg, P ¼ .0016; mean scores, Figure 5C, Supplementary
Table 3). Mean reductions in adjusted EoEHSS grade
scores of 32.126 ± 13.641 and 30.694 ± 17.128 and mean
reductions in adjusted EoEHSS stage scores of 25.529 ±
12.660 and 27.374 ± 14.669 between either RPC4046
dose (180 mg, n ¼ 12; 360 mg, n ¼ 15) and placebo
(n ¼ 15) were statistically signiﬁcant at week 16
(P < .0001 for all comparisons; Figure 5D; Supplementary
Table 8). The reduction in EEsAI PRO score between
the 360-mg RPC4046 and placebo groups was signiﬁcant
(P ¼ .0393), whereas the difference between the 180-mg
RPC4046 and placebo groups was not (Figure 5E;
Supplementary Table 9).
Safety Assessment
The frequency of adverse events was numerically
higher in the 360-mg RPC4046 group. The most common
treatment-emergent adverse events observed were head-
ache, upper respiratory tract infection, arthralgia, naso-
pharyngitis, diarrhea, and nausea (Table 2). Overall, the
frequency of treatment-emergent adverse events in the
RPC4046 treatment groups was low and similar to pla-
cebo. Four patients discontinued study drug due to a
treatment-emergent adverse event (1 patient receiving
180 mg [dizziness], 3 patients receiving 360 mg [inﬂuenza-
like illness, pruritus and rash, and worsening of EoE
symptoms]). Three patients experienced a serious adverse
event, all of which were considered unrelated to study
drug (2 patients receiving placebo [umbilical hernia,
appendicitis], 1 patient receiving 360 mg [appendicitis])(Supplementary Table 6). Two patients receiving 180 mg
and no patients receiving 360 mg developed anti-drug
antibodies.
Serious adverse events and injection site treatment-
emergent adverse events are shown in Supplementary
Tables 10 and 11, respectively. One serious adverse event
of umbilical hernia in the placebo group and 2 serious
adverse events of appendicitis (1 in the placebo group and 1
in the 360-mg RPC4046 group) were reported. The most
common injection site treatment-emergent adverse events
were injection site pain (8.8%) in the placebo group and
injection site erythema (8.8%) in the 360-mg RPC4046
group. Each injection site event that was reported in the
180-mg RPC4046 group occurred in no more than a single
patient.Discussion
In this phase 2 trial of patients with active EoE, 180-mg
and 360-mg RPC4046 demonstrated greater beneﬁt than
placebo in reducing esophageal eosinophil count at week 16.
Furthermore, signiﬁcant reductions in histologic and endo-
scopic assessment of disease activity were demonstrated
using validated instruments. These results were seen both
in the overall population and in the steroid-refractory
subgroup.
IL13 has been implicated as a key cytokine in the
pathogenesis of EoE. Signiﬁcant reductions in EoE disease
activity following RPC4046 treatment in this study highlight
the clinical relevance of targeting IL13 as a therapeutic
approach for this disorder. These results further extend and
support preliminary data from a small proof-of-concept
study in EoE using a different antibody against IL13,15 as
well as in vivo modeling in mice, in which IL13 over-
expression has been shown to be sufﬁcient to induce an
EoE-like disease process.11 Indeed, IL13 is markedly over-
expressed in the esophagus of patients with EoE and
induces EoE-like changes in esophageal epithelial cells,7
including a subset of the EoE transcriptome, impaired bar-
rier formation,10 and production of the eosinophil chemo-
attractant and activating factor eotaxin-37 and induction of
the gene product encoded by the primary EoE genetic risk
factor, CAPN14, which regulates esophageal barrier func-
tion, which is impaired in EoE.13
Although reductions in dysphagia symptoms assessed by
the DSD composite score and the EEsAI PRO score were not
statistically signiﬁcant with RPC4046 at either dose level
compared with placebo, a strong trend was observed with
the 360-mg RPC4046 dose. Furthermore, patient and clini-
cian global PRO measures demonstrated signiﬁcant reduc-
tion in overall perceptions of disease severity with
RPC4046. These ﬁndings are notable, as the study was not
powered to show differences in symptom metrics. Concep-
tually, reducing dysphagia symptoms may be more difﬁcult
to achieve than reducing mucosal inﬂammation owing to the
contribution of subepithelial ﬁbrostenoic remodeling.
Nevertheless, the trend for a reduction in symptoms that
was detected in spite of the small sample size is encouraging
for further development of RPC4046.
Figure 5. For steroid-refractory subgroup, mean esophageal eosinophil count (eos/hpf) at baseline and week 16 (primary
endpoint) (A). Mean change over the 14 days preceding each study visit in dysphagia symptom diary (DSD) score (± standard
error) at baseline and weeks 4, 8, 12, and 16 (P ¼ .0733 for 360 mg at week 16; daily DSD score range: 0‒6, with higher scores
indicating more severe dysphagia symptoms) (B). Mean total EREFS at baseline and week 16 (endoscopic ﬁndings analyzed
according to modiﬁed scoring system described by Hirano et al 201318; total EREFS score range: 0‒8 for each location [ie,
total score range across 3 locations: 0‒24]) (C). Mean changes from baseline to week 16 in eosinophilic histology grade (range:
0‒3 for each of 8 features for proximal and distal biopsies [ie, total score range: 0‒48]) and stage (range: same as for grade)
scores (D). Mean change in the EEsAI score (± standard error) at weeks 4, 8, 12, and 16 (P ¼ .0852 for 180 mg and P ¼ .0393
for 360 mg at week 16) (E).
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ATWe did not identify any serious safety issues, although
the trial was not large enough or of sufﬁcient duration to
fully assess the long-term safety of RPC4046 treatment of
adults with EoE. A higher percentage of patients experi-
enced adverse events with the 360-mg RPC4046 dosecompared with the 180-mg RPC4046 dose or placebo. The 3
most frequently reported events were headache, upper
respiratory tract infection, and arthralgia.
Current EoE management relies primarily on off-label
use of swallowed corticosteroids or dietary elimination of
Table 2.Summary of Safety Findings by Study Group During the Double-blind Treatment Period
Placebo (n ¼ 34)
RPC4046
180 mg (n ¼ 31) 360 mg (n ¼ 34)
No. of patients experiencing adverse events 103 99 127
Adverse event, n (%) 22 (64.7) 20 (64.5) 29 (85.3)
Serious adverse eventa, n (%) 2 (5.9) 0 1 (2.9)
Adverse event leading to discontinuation of regimen, n (%) 0 1 (3.2) 3 (8.8)
Adverse event occurring in 2 patients in either RPC4046
treatment group, n (%)
Headache 5 (14.7) 5 (16.1) 7 (20.6)
Upper respiratory tract infection 3 (8.8) 5 (16.1) 5 (14.7)
Arthralgia 0 4 (12.9) 2 (5.9)
Nasopharyngitis 0 3 (9.7) 3 (8.8)
Diarrhea 2 (5.9) 3 (9.7) 2 (5.9)
Nausea 4 (11.8) 2 (6.5) 3 (8.8)
Abdominal pain 0 2 (6.5) 2 (5.9)
Dizziness 2 (5.9) 3 (9.7) 1 (2.9)
Oropharyngeal pain 0 1 (3.2) 3 (8.8)
Sinusitis 0 3 (9.7) 1 (2.9)
Vomiting 2 (5.9) 1 (3.2) 3 (8.8)
Contact dermatitis 0 1 (3.2) 2 (5.9)
Fatigue 1 (2.9) 2 (6.5) 1 (2.9)
Injection site erythema 2 (5.9) 0 3 (8.8)
Urticaria 0 2 (6.5) 1 (2.9)
Myalgia 0 1 (3.2) 2 (5.9)
Contusion 1 (2.9) 2 (6.5) 0
Cough 1 (2.9) 2 (6.5) 0
Gastroenteritis 1 (2.9) 2 (6.5) 0
Hypersensitivity 0 0 2 (5.9)
Injection site hematoma 0 0 2 (5.9)
Injection site pruritus 1 (2.9) 0 2 (5.9)
Ligament sprain 1 (2.9) 0 2 (5.9)
aA serious adverse event was deﬁned as any untoward medical occurrence that resulted in death, was life-threatening (has an
immediate risk of death), required admission to a hospital or prolongation of existing hospitalization, resulted in persistent or
signiﬁcant disability or incapacity, or resulted in a congenital anomaly or birth defect.
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ATputative allergic triggers.21 Although steroids are effective at
decreasing esophageal eosinophilia, their ability to reduce
symptoms has been modest and variable. Furthermore,
heterogeneity in the histologic response has been demon-
strated with rates of corticosteroid resistance as high as
40% to 60% reported in several studies.6,7,22 Drawbacks of
steroid use include disease recurrence upon cessation of
daily administration, esophageal candidiasis, possible loss of
response with prolonged use,23,24 as well as potential long-
term side effects. It also remains uncertain if topical thera-
pies will be effective for subepithelial remodeling. Diet
therapies offer a nonpharmacologic strategy but lack an ac-
curate test to identify trigger foods. Moreover, the prospect of
long-term cessation of the most common food triggers, such
as milk, wheat, soy, and egg, is unacceptable to many pa-
tients. Thus, alternative treatment options are needed.
Approximately half of the enrolled patients were
categorized as being steroid refractory. Such patients
represent an increasingly recognized, clinically relevant, and
difﬁcult-to-treat subgroup of EoE. Prospective studies have
identiﬁed that >50% of patients treated with topicalsteroids failed to sustain an initial histologic response with
longer-term administration.23,24 In the present study, it is
notable that signiﬁcant reductions in esophageal eosinophil
counts, histologic features, and endoscopic features were
observed in steroid-refractory patients following treatment
with RPC4046. Interestingly, the reduction in dysphagia
symptoms, as measured by the DSD and EEsAI, was more
pronounced with the 360-mg RPC4046 dose in the steroid-
refractory subset than in the overall patient group.
The potential role for biologic therapies such as
RPC4046, in the management of EoE has yet to be deﬁned.
Patients refractory to corticosteroids are a logical initial
target population in EoE. Increasing data support trans-
mural inﬂammatory activity and remodeling consequences
of EoE.8,25 Systemically active therapeutics offer conceptual
advantages over topical steroids that target the epithe-
lium.8,26,27 Finally, although yet unproven, the proposed
beneﬁts of IL13 blockade in terms of remodeling aspects of
disease may prevent disease progression and disease com-
plications, including esophageal strictures and food
impactions.
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ATOur study had several limitations. The study was not
powered to assess reduction in dysphagia symptoms;
however, a strong trend was observed with the 360-mg
RPC4046 dose. Furthermore, a validated PRO for EoE
symptoms was not available at the time the study was
designed. Although steroid-refractory status was pre-
speciﬁed for purposes of patient allocation, the designation
was determined by the investigator. A uniform deﬁnition of
steroid resistance would have provided better clarity in
deﬁning this important subgroup. Given the 16-week
duration of observation and the small number of patients
evaluated, we cannot establish the long-term efﬁcacy or
safety of RPC4046 in patients with EoE.
Important strengths of our study include the signiﬁcant
reduction in disease activity based on endoscopic (EREFS)
and histologic (EoEHSS) outcome measures that were spe-
ciﬁcally designed and validated for EoE. In fact, the current
study was the ﬁrst clinical trial of biologic therapy in EoE to
incorporate use of either the EREFS or the EoEHSS in-
struments. The study is the largest clinical trial of therapy
targeting IL13 and the largest adult trial of a biologic agent
in EoE. We also believe that the use of a centralized, blinded
pathologist with expertise in eosinophilic disorders in-
creases the accuracy of the histologic assessment with the
EoEHSS.
In conclusion, data from this phase 2 trial provide
evidence of the efﬁcacy and safety of RPC4046 (a mono-
clonal antibody against IL13) in adult patients with EoE,
with reduction in histopathologic and endoscopic aspects
of disease activity and global perception of disease
severity. These data substantiate the key contribution of
IL13 to the pathogenesis of EoE and support the further
study of RPC4046 as a novel, targeted approach for pa-
tients with EoE.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2018.10.051.References
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Study Investigators at Initiated Sites
Country Investigator name Institution name
Canada Donnellan, Fergal Vancouver Hospital
Gastrointestinal Research Unit
The Gordon and Leslie Diamond Centre
Canada Iacucci, Marietta Gastrointestinal Research Group, University of Calgary Health
Canada Paterson, William Hotel Dieu Hospital
Switzerland Schoepfer, Alain Centre Hospitalier Universitaire Vaudois (CHUV)
Switzerland Straumann, Alex Swiss EoE Clinic
USA Abonia, Pablo Cincinnati Children’s Hospital Medical Center
USA Assouline-Dayan, Yehudith University of Iowa Hospitals and Clinics
USA Ayub, Kamran Southwest Gastroenterology
USA Coates, Allan West Michigan Clinical Research Center
Gastroenterology Associates of Western Michigan
USA Cohen, Sidney Thomas Jefferson University
USA Dellon, Evan University of North Carolina
USA Desta, Taddese Precision Research Institute, LLC
USA Evans, Larry Grand Teton Research Group
USA Falk, Gary The University of Pennsylvania
USA Fein, Steven Digestive Health Center
USA Fernandez-Becker, Nielsen Stanford University
USA Fleischer, David Children’s Hospital Colorado
USA Friedenberg, Keith Great Lakes Gastroenterology Research
USA Ghishan, Fayez The University of Arizona Clinical and Translational Science
USA Glover, Sarah University of Florida
USA Goldstein, Gary Visions Clinical Research
USA Gopal, Vikram Borland-Groover Clinic
USA Gross, Craig Desert Sun Clinical Research, LLC
USA Hardi, Robert Metropolitan Gastroenterology Group Chevy Chase Clinical Research
USA Hirano, Ikuo Northwestern University
USA Kugathasan, Subra Emory University
USA Lacy, Brian Dartmouth-Hitchcock Medical Center
USA Lewis, Jeffery Children’s Center for Digestive Healthcare
USA Menard-Katcher, Paul University of Colorado Anschutz Medical Center
USA1 Mitlyng, Benjamin Minnesota Gastroenterology
USA Moawad, Fouad Walter Reed Army Medical Center
USA Perez, Rodney Asheville Gastroenterology Associates, PA
USA Peterson, Kathryn University of Utah
USA Ramirez, Francisco Mayo Clinic in Arizona, Clinical Studies Unit
USA Reeves-Darby, Vonda Gastrointestinal Associates
USA Schey, Ron Temple University Hospital
USA Shad, Javaid Alliance Clinical Research
USA Vaezi, Michael Vanderbilt University Medical Center
USA Wo, John Indiana University
USA Zakko, Salam Connecticut Clinical Research Foundation
NOTE: The 40 listed sites were initiated for participation in this study; of these sites, 30 enrolled at least 1 subject.
Study Administration
The members of the HEROES protocol committee
designed the trial in collaboration with Celgene. Study data
were collected by a contract research organization (Agility
Clinical, Inc.) and analyzed by Celgene. Celgene and the
HEROES study group interpreted the data jointly and safety
data were reviewed by a safety review. All authors had full
access to the data. The ﬁrst author wrote the ﬁrst draft of
the manuscript, and all authors contributed to subsequent
drafts, made a collective decision to submit the manuscript
for publication, and vouch for the completeness and veracity
of the data and analyses and for the adherence to the
protocol, available at NEJM.org. Editorial support was pro-
vided by Celgene. Conﬁdentiality agreements were in place
between Celgene and all authors.
603.e1 Hirano et al Gastroenterology Vol. 156, No. 3
Protocol Committee
Evan S. Dellon, MD
UNC School of Medicine
130 Mason Farm Road
4140 Bioinformatics Building
Campus Box 7080
Chapel Hill, NC 27599–7080, USA
Phone: 919–843–9618
E-mail: edellon@med.unc.edu
Ikuo Hirano, MD
Northwestern University Feinberg School of Medicine
Division of Gastroenterology
676 N. St. Clair, Suite 1400
Chicago, IL 60611, USA
Telephone: 312–695–4036
E-mail: i-hirano@northwestern.edu
Alex Straumann, MD
Swiss EoE Clinic
Roemerstrasse 7
Olten, 4600 Switzerland
Telephone: þ41 62 212 55 77
E-mail: alex.straumann@hin.ch
Alain M. Schoepfer, MD
Centre Hospitalier Universitaire Vaudois (CHUV)
Rue du Bugnon 44, Bureau 07/2409
Lausanne, 1011 Switzerland
Telephone: þ41 21 314 2394
E-mail: alain.schoepfer@chuv.ch
Safety Review Committee
Sandeep Gupta, MD
Professor of Clinical Pediatrics and Clinical Medicine
University of Illinois College of Medicine
1 Illini Drive
Peoria, IL 61605, USA
Telephone: 317–944–3774
E-mail: sgupta@iupui.edu
Paul Frohna, MD, PhD, PharmD
Formerly with Receptos, a wholly owned subsidiary of
Celgene, Inc.
3033 Science Park Road, #300 San Diego, CA 92121, USA
Telephone: 858–652–5700
E-mail: pharmer88@gmail.com
Michael Grimm, MD
Formerly with Receptos, a wholly owned subsidiary of
Celgene, Inc.
3033 Science Park Road, #300
San Diego, CA 92121, USA
Telephone: 858–652–5700
E-mail: fmgrimm@yahoo.com
Inclusion Criteria
The following criteria were also required for study
inclusion: Subjects with a partial response to a proton pump
inhibitor (PPI) who met all other eligibility criteria could be
enrolled; prospective subjects who discontinued use of a PPI
had to wait at least 4 weeks before their screening endos-
copy; if a prospective subject was receiving a PPI at
screening, the subject must have been receiving a stable
dose for at least 4 weeks before the screening endoscopy
and agreed to continue on the same dose through week 16;
men and women of childbearing potential had to agree to
use adequate birth control measures during the trial and for
5 months after their last dose of study drug; all women of
childbearing potential must have had a negative serum
pregnancy test at screening and a negative urine (or serum)
pregnancy test before dosing on day 1.
Exclusion Criteria
Exclusion criteria included clinical or endoscopic
evidence of the presence of any other disease that may have
interfered with or affected the histologic, endoscopic, and
clinical symptom endpoints for this trial (eg, erosive
esophagitis grade 2 or above, Barrett’s disease, upper
gastrointestinal bleed, eosinophilic gastritis or gastroenter-
itis, duodenal or gastric eosinophilia on screening endos-
copy, inﬂammatory bowel disease, signiﬁcant hiatal hernia
[>3 cm]); presence of esophageal varices; evidence of
severe endoscopic structural abnormality in esophagus (eg,
high-grade stenosis where an 8- to 10-mm endoscope could
not pass through the stricture without dilation at the time of
endoscopy); primary causes of esophageal eosinophilia
other than EoE; evidence of immunosuppression or were
receiving systemic immunosuppressive or immunomodu-
lating drugs (eg, methotrexate, cyclosporine, interferon
alpha, tumor necrosis factor alpha inhibitors, antibodies to
immunoglobulin E) within 5 drug half-lives before
screening; were receiving systemic or swallowed topical
corticosteroid medication; prospective subjects with EoE
treated with a corticosteroid must have not received a
systemic corticosteroid within 8 weeks or swallowed topical
corticosteroids within 4 weeks of the screening endoscopy
or the start of the daily clinical symptom diary data collec-
tion during screening, whichever was performed ﬁrst;
presence of any other disease making conduct of the pro-
tocol or interpretation of the trial results difﬁcult or that
would have put the prospective subject at risk by partici-
pating in the trial (eg, infection causing eosinophilia,
gastritis, colitis, irritable bowel syndrome, and celiac dis-
ease, which have similar symptoms, neurologic or psychi-
atric illness that compromised the prospective subject’s
ability to accurately document symptoms of EoE); liver
function impairment or persisting elevations of aspartate
aminotransferase or alanine aminotransferase >2 times the
upper limit of normal (ULN), or direct bilirubin >1.5 times
the ULN; systemic or diarrheal illness following travel or
residence in endemic areas of parasitic/helminthic
infections, history of clinical schistosomiasis, history of
travel to endemic areas within preceding 6 months; ongoing
infection (eg, hepatitis B or C, human immunodeﬁciency
virus, active tuberculosis); pregnancy or lactation; concur-
rent treatment with another investigational drug; prospec-
tive subjects could not have participated in a concurrent
investigational drug trial or have received an investigational
drug within 5 drug half-lives before signing the informed
consent form for this trial; weight less than 40 kg (88.2
pounds) or greater than 125 kg (275 pounds); history of
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idiopathic anaphylaxis or a known history of a major
immunologic reaction (such as anaphylactic reaction,
anaphylactoid reaction, or serum sickness) to an immuno-
globulin G–containing agent; history of cancer or lympho-
proliferative disease, other than a successfully treated
nonmetastatic cutaneous squamous cell or basal cell carci-
noma or adequately treated cervical carcinoma in situ,
within 10 years of screening; esophageal dilation for
symptom relief during the screening period and within 4
weeks before baseline assessment of dysphagia or antici-
pated to be performed during the trial.
Protocol Amendments
The original protocol (dated March 13, 2014) was
amended 3 times. The ﬁrst amendment (dated May 16,
2014) was implemented before enrollment of the ﬁrst
patient in the study (September 3, 2014). Summaries of the
major changes included in each amendment are provided as
follows.
Protocol Amendment 1 (dated May 16, 2014):
 Removed the open-label extension (OLE) to shorten the
total duration of treatment to 16 weeks to be consistent
with the available toxicology data at that time, with the
potential to add an OLE after completion of a then
ongoing longer-term toxicology study
 Extended the duration of double-blind dosing from 12
weeks to 16 weeks, with the longer duration of double-
blind treatment expected to have a greater impact on
eosinophil count and increased clinical beneﬁt
 Changed the time point for efﬁcacy endpoints from
week 12 to week 16 to be consistent with the increased
duration of double-blind treatment
 Added a week 2 visit to assess antidrug antibody (ADA)
and pharmacokinetic data to provide an earlier time
point for these assessments
 Increased the lower limit of the eligible age range from
12 years to 18 years to address concerns about ado-
lescents potentially receiving placebo and being
exposed to more than minimal risk
 Increased the lower weight limit to 40 kg in alignment
with removal of adolescents from the trial
 Added an exclusion criterion for subjects requiring
esophageal dilation for symptom relief within 4 weeks
before baseline assessment of dysphagia or anticipated
to be performed during the trial; this change was
made because use of esophageal dilation could amelio-
rate strictures in symptomatic subjects and would
therefore confound efﬁcacy assessment in this trial
 Reduced the number of biomarkers to be assessed
 Modiﬁed the restriction for concurrent medication to
treat asthma or allergies during the trial to enable the
Investigator to contact the Medical Monitor to discuss
treatment options if changes to treatments are required,
providing more ﬂexibility for the physician to treat
without withdrawal of the subject
Protocol Amendment 2 (dated October 17, 2014):
 Updated data from nonclinical toxicology studies to
report that no observed adverse effects levels were
established at the highest dose evaluated in general
toxicology studies in rats and cynomolgus monkeys and
that once-weekly SC injection of 20, 60, or 300 mg/kg
RPC4046 or IV administration of 300 mg/kg RPC4046
for 26 consecutive weeks (26 total doses) to cyn-
omolgus monkeys was well tolerated at all dose levels
 Extended treatment by an optional 24-week OLE
 Removed the Esophageal String Test due to limited
availability of the test
 Speciﬁed the requirement for collection of daily
dysphagia symptom diary (DSD) for the past 2 consec-
utive weeks (± 3 days) before day 1
 Added text regarding the day 1 IV loading dose þ SC
dose, and SC doses once weekly for 15 additional weeks
to avoid confusion regarding the number of weekly SC
doses to be administered in the double-blind treatment
period
 Modiﬁed inclusion criteria as follows:
– Criterion 1: clariﬁcation that diagnosis of EoE must be
conﬁrmed before randomization
– Criterion 3: clariﬁcation that histological evidence of
EoE can come from any 2 levels of the esophagus
– Criterion 5: requirement for birth control use for
5 months after last dose of RPC4046 to coincide with
elimination or clearance of the half-life of RPC4046
clearance (ie, 5 times the half-life of 1 month)
 Modiﬁed exclusion criteria as follows:
– Criterion 10: speciﬁcation that ongoing infections
include active tuberculosis
– Criterion 15: no history of cancer within 10 years of
screening
 Changed IV stability dose to 8 hours at 2 to 8C
 Clariﬁed food restriction diet and added instruction
regarding environmental therapy
 Clariﬁed requirement to not use systemic or swallowed
topical corticosteroids
 Speciﬁed that the blind in the trial was not to be broken
until all subjects completed the double-blind treatment
period (unless medically necessary)
 Added a coagulation panel during each hematology and
chemistry assessment
 Extended the period of adverse event (AE) collection to
30 days after last dose or last visit
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 Added text to clearly deﬁne the intent-to-treat and per-
protocol populations
Protocol Amendment 3 (dated June 22, 2015):
 Extended the OLE from 24 weeks to 52 weeks
 Removed the interim analysis from the protocol
Methods
Blinded Dosing Regimen. The placebo and RPC4046
dose formulations were identical in appearance. All patients
received an identical study drug regimen consisting of SC
administration of placebo or RPC4046 180 mg or RPC4046
360 mg.
Initial Study Dose. The initial dose was administered
as a 2-hour IV infusion (placebo or 5 mg/kg or 10 mg/kg)
plus two 1.2-mL SC injections (placebo or RPC4046 180 mg
or RPC4046 360 mg) in the clinic on day 1.
Weekly Study Dose. After day 1, dosing with two
1.2-mL SC injections of study drug continued weekly
through week 15.
Immunogenicity Assessment
A validated ECL-based assay was used to measure ADA
response. A preliminary assessment was performed of the
presence of neutralizing ADA through comparison of
RPC4046 pharmacokinetics in ADA (þ) and ADA ()
subjects.
Most subjects were ADA () at all visits. Two subjects,
both in the RPC4046 180-mg group, tested positive for ADA
during the study.
One subject was ADA (þ) on day 1 and week 12 and was
ADA () on weeks 2, 4, 8, and 16. This subject had a mild
treatment-emergent AE (TEAE) of injection site pain
(verbatim term: burning at all injection sites) on day 1 that
was assessed as possibly related to study drug and had an
unknown outcome. No other TEAEs were reported.
One subject was ADA () at all visits from day 1 through
week 8 and was ADA (þ) at weeks 12 and 16. This subject
had the following TEAEs during the study: mild TEAE of
feeling hot (verbatim term: feeling hot: no fever, no ﬂushing,
no sweating) assessed as probably related to study drug
(day 1); 2 TEAEs of upper respiratory tract infection, 1 mild
and unrelated (days 3–8) and 1 moderate and possibly
related to study drug (days 25–36); a mild TEAE of
gastroenteritis that was unlikely related to study drug (day
32); and a mild TEAE of nasopharyngitis that was unlikely
related to study drug (days 99–108).
No subjects in the RPC4046 360-mg group were ADA
(þ) at any time during the study.
Key Secondary Efﬁcacy Endpoint: Daily
Dysphagia Symptom Diary
The key secondary efﬁcacy endpointwas themean change
from baseline to week 16 in the dysphagia clinical symptom
frequency and severity as assessed by a daily DSD completed
over 2 weeks before each visit. As with the primary endpoint,
analysis of subgroups for the key secondary endpoint was
prespeciﬁed and included the following: subjects known to be
steroid-refractory and subjects not known to be steroid-
refractory; subjects with baseline daily DSD composite
score of severity  median and > median; and subjects with
5 years and >5 years since EoE diagnosis.
Daily Dysphagia Symptom Diary Questions
An interactive Web-based or phone response system
was used by subjects to complete the DSD. Subjects were
able to access the DSD by phone and/or by Internet.
The following questions were included in the DSD:
 Question 1: Did you try to eat solid food today?
 Yes (go to Question 2)
 No (go to Question 1a)
 Question 1a: What is the primary reason you did not try
to eat solid food today?
EoE symptoms
Reason other than EoE symptoms
 Question 2: During any meal today, did food go down
slowly or get stuck in your throat or chest?
Yes
No
 Question 3: For the most difﬁcult time you had swal-
lowing today, did you have to do anything to make the
food go down or to get relief?
If Question 2 is no,
If Question 2 is yes:
– No, it got better or cleared up on its own
– Yes, I had to drink liquid to get relief
– Yes, I had to cough and or gag to get relief
– Yes, I had to vomit to get relief
– Yes, the stuck food had to be removed by a doctor
 Question 4: Did you have any pain associated with
swallowing food today?
Yes
No
 Question 4a: How would you rate your pain associated
with swallowing food today?
Range 1 (minimal pain) – 10 (worst pain imaginable)
Subjects completed the DSD for at least the last 2 weeks ±
3 days during the screening period before day 1 and daily
from day 1 through week 16. In addition, subjects completed
the DSD for the 2 weeks before the safety follow-up visit on
week 24 (if applicable).
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Eosinophilic Esophagitis Endoscopic Reference
Score (EREFS)
The esophageal mucosal endoscopic features of EoE
were assessed by each investigator using the EREFS1 in 5
classiﬁcation categories at screening, week 16, or if appli-
cable at early termination. Grades for each feature and total
scores were calculated for the following features:
 Fixed rings: 0 (none), 1 (mild), 2 (moderate), or 3
(severe)
 Exudates: 0 (none), 1 (mild), or 2 (severe)
 Furrows: 0 (none) or 1 (present)
 Edema: 0 (none) or 1 (present)
 Stricture: 0 (none) or 1 (present)
The EoE histology grade score was recorded indepen-
dently in the proximal, mid, and distal esophagus as the sum
of 8 features (basal zone hyperplasia, peak eosinophil count,
abscesses, surface layering, dilated intercellular spaces, sur-
face alteration, apoptotic epithelial cells, and lamina propria
ﬁbrosis). A total possible scorewas recordedbasedon features
thatwerenot evaluable.Eachof the locationswas standardized
to a single score based on the following formula: Adjusted
Score ¼ (Total Score)/(Total Possible Score) 100. The EoE
histology stage score, which was recorded for the same 8
features, was calculated in the same manner.
Eosinophilic Esophagitis Endoscopic Histology
Grade and Stage Score
The esophageal histologic changes characteristic of EoE
were assessed by examining 8 parameters2:
 Eosinophil inﬂammation was graded using peak eosin-
ophil count obtained by counting eosinophils in the
most densely inﬂamed high-power ﬁeld
 Basal zone hyperplasia: >15% of the total epithelial
thickness
 Eosinophil abscess: solid mass of intraepithelial
eosinophils
 Eosinophil surface layering: linear alignment of eosin-
ophils parallel to the epithelial surface
 Dilated intracellular spaces: spaces around squamous
epithelial cells that exhibit intercellular bridges
 Surface epithelial alteration: surface epithelial cells that
exhibit altered tinctorial properties, manifest as dark
staining, with or without intraepithelial eosinophils
 Dyskeratotic epithelial cells: individual cells with deeply
eosinophilic cytoplasm and hyperchromatic nuclei
 Lamina propria ﬁbers: thickened connective tissue ﬁ-
bers in the lamina propria.
Each feature was scored separately for grade (severity)
or stage (extent) of abnormality using a 4-point scale (0 ¼
normal; 3 ¼ most severe or extensive).
Eosinophilic Esophagitis Activity Index (EEsAI)
The EEsAI is another paper-based PRO symptom
instrument assessing changes in dysphagia caused by
foods of various consistencies, behavioral adaptations to
living with EoE, and swallowing-associated pain. The
EEsAI uses a 7-day recall period. Based on summation of
individual scores for EEsAI categories, a total score be-
tween 0 and 100 is possible. The mean change from
baseline to week 16 in the dysphagia clinical symptoms
frequency and severity as assessed by the EEsAI was a
secondary endpoint.
Clinician and Subject Global Assessment of
Disease Severity
Clinicians assessed subject disease severity on a scale
from 0 to 10, where 0 ¼ no evidence of disease and 10 ¼
worst possible evidence of disease. Subjects assessed their
disease severity on a scale from 0 to 10, where 0 ¼ no
symptoms and 10 ¼ worst symptoms possible.
Categorical Analysis of Subject’s Global
Impression of Change
Subjects assessed their impression of change of their
disease based on 5 categories, including a lot better, a
little better, stayed the same, a little worse, and much
worse.
References
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Supplementary Table 1.Participants Across Study Sites by Country
Country Site
Placebo
(n ¼ 34) n (%)
RPC4046 180 mg
(n ¼ 32) n (%)
RPC4046 180 mg
(n ¼ 32) n (%)
Total
(N ¼ 100) n (%)
United States 102 4 (11.8) 4 (12.5) 3 (8.8) 11 (11.0)
104 1 (2.9) 2 (6.3) 4 (11.8) 7 (7.0)
106 2 (5.9) 3 (9.4) 2 (5.9) 7 (7.0)
107 4 (11.8) 1 (3.1) 0 5 (5.0)
112 1 (2.9) 3 (9.4) 0 4 (4.0)
115 2 (5.9) 2 (6.3) 1 (2.9) 5 (5.0)
116 0 2 (6.3) 3 (8.8) 5 (5.0)
118 0 1 (3.1) 1 (2.9) 2 (2.0)
121 0 0 1 (2.9) 1 (1.0)
122 1 (2.9) 0 0 1 (1.0)
124 0 0 1 (2.9) 1 (1.0)
125 2 (5.9) 0 3 (8.8) 5 (5.0)
126 0 1 (3.1) 0 1 (1.0)
130 1 (2.9) 2 (6.3) 0 3 (3.0)
132 0 1 (3.1) 0 1 (1.0)
133 1 (2.9) 0 0 1 (1.0)
135 1 (2.9) 0 0 1 (1.0)
136 1 (2.9) 1 (3.1) 1 (2.9) 3 (3.0)
139 0 0 3 (8.8) 3 (3.0)
140 1 (2.9) 0 0 1 (1.0)
141 0 1 (3.1) 0 1 (1.0)
143 4 (11.8) 1 (3.1) 1 (2.9) 6 (6.0)
144 3 (8.8) 2 (6.3) 6 (17.6) 11 (11.0)
145 1 (2.9) 2 (6.3) 0 3 (3.0)
146 0 1 (3.1) 1 (2.9) 2 (2.0)
147 1 (2.9) 0 0 1 (1.0)
148 0 0 1 (2.9) 1 (1.0)
Canada 202 1 (2.9) 0 0 1 (1.0)
Switzerland 301 2 (5.9) 2 (6.3) 1 (2.9) 5 (5.0)
302 0 0 1 (2.9) 1 (1.0)
Supplementary Table 2.Baseline Characteristics of Steroid-refractory and Non–steroid-refractory Patients
Steroid refractory ¼ Yes Steroid refractory ¼ No
Placebo
(n ¼ 16)
RPC4046
180 mg (n ¼ 14)
RPC4046
360 mg (n ¼ 17)
Placebo
(n ¼ 18)
RPC4046
180 mg (n ¼ 17)
RPC4046
360 mg (n ¼ 17)
Years since EoE Diagnosis
Mean (SD) 5.2 (2.9) 6.0 (4.7) 4.1 (2.5) 3.4 (2.6) 2.8 (2.2) 3.7 (3.0)
Min, Max 0.20, 10.89 0.61, 15.52 0.60, 9.05 0.14, 9.12 0.12, 6.52 0.04, 9.53
Peak eosinophil count/hpf
Mean (SD) 92.3 (55.6) 162.8 (91.0) 141.6 (82.5) 117.0 (63.7) 106.4 (71.8) 137.1 (79.8)
Min, Max 18, 201 42, 304 51, 389 31, 212 24, 281 26, 328
Mean eosinophil count/hpf
Mean (SD) 79.2 (47.1) 146.9 (83.1) 127.5 (78.2) 104.1 (58.5) 91.8 (64.3) 117.6 (65.2)
Min, Max 17.6, 158.8 32.6, 273 42.2, 369.2 23.6, 189.8 21.4, 239.2 22.2, 264.4
DSD score
Mean (SD) 32.7 (12.0) 26.9 (14.6) 29.3 (9.4) 26.9 (9.1) 28.5 (11.9) 28.8 (11.0)
Min, Max 11, 51 6.6, 52 11, 42 14, 48 12, 51 13, 49
DSD, daily dysphagia symptom diary; hpf, high-power ﬁeld; Max, maximum; Min, minimum; SD, standard deviation.
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Supplementary Table 3. Inﬂammatory Component (Edema, Exudate, Furrows) and Stenosis (Fixed Rings, Stricture)
Component of Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) for Total Population
and Steroid-refractory Group
Total population Steroid-refractory subjects
Placebo
(n ¼ 34)
RPC4046
180 mg (n ¼ 31)
RPC4046
360 mg (n ¼ 34)
Placebo
(n ¼ 16)
RPC4046
180 mg (n ¼ 14)
RPC4046
360 mg (n ¼ 17)
Total score
Baselinea n ¼ 32 n ¼ 27 n ¼31 n ¼ 14 n ¼ 14 n ¼ 15
Mean (SD) 9.1 (4.3) 9.0 (4.4) 9.4 (4.3) 10.7 (3.8) 9.9 (4.8) 9.7 (3.9)
Week 16 n ¼ 32 n ¼ 27 n ¼ 30 n ¼ 14 n ¼ 12 n ¼ 15
Mean (SD) 7.9 (5.1) 5.3 (4.2) 4.8 (3.4) 10.4 (4.7) 5.8 (4.9) 5.3 (3.7)
P valueb .0004 <.0001 .0026 .0016
Edema
Baselinea n ¼ 32 n ¼ 27 n ¼ 31 n ¼ 14 n ¼ 14 n ¼ 15
Mean (SD) 1.7 (1.4) 1.9 (1.4) 2.1 (1.2) 2.1 (1.3) 2.1 (1.4) 2.1 (1.1)
Week 16 n ¼ 32 n ¼ 28 n ¼ 30 n ¼ 14 n ¼ 12 n ¼ 15
Mean (SD) 1.7 (1.4) 1.2 (1.4) 1.2 (1.4) 2.6 (0.9) 1.1 (1.4) 1.4 (1.3)
P valueb .0116 .0156 .0002 .0036
Exudates
Baselinea n ¼ 32 n ¼ 27 n ¼ 31 n ¼ 14 n ¼ 14 n ¼ 15
Mean (SD) 1.4 (1.7) 2.3 (1.9) 1.8 (2.0) 1.9 (1.9) 2.6 (1.6) 2.1 (1.8)
Week 16 n ¼ 32 n ¼ 27 n ¼ 30 n ¼ 14 n ¼ 12 n ¼ 15
Mean (SD) 1.2 (1.5) 0.5 (1.0) 0.5 (0.9) 1.7 (1.8) 0.3 (0.8) 0.9 (1.1)
P valueb .0022 .0159 .0045 .0665
Furrows
Baselinea n ¼ 32 n ¼ 27 n ¼ 31 n ¼ 14 n ¼ 14 n ¼ 15
Mean (SD) 2.3 (1.1) 2.1 (1.2) 2.4 (0.8) 2.6 (0.9) 1.9 (1.3) 2.7 (0.5)
Week 16 n ¼ 32 n ¼ 27 n ¼ 30 n ¼ 14 n ¼ 12 n ¼ 15
Mean (SD) 1.9 (1.1) 1.0 (1.2) 0.8 (1.0) 2.1 (1.0) 1.1 (1.2) 0.8 (1.2)
P valueb .0002 <.0001 .0328 .0018
Fixed rings
Baselinea n ¼ 32 n ¼ 27 n ¼ 31 n ¼ 14 n ¼ 14 n ¼ 15
Mean (SD) 3.0 (1.9) 2.1 (1.5) 2.8 (2.2) 3.1 (1.3) 2.6 (1.8) 2.5 (2.1)
Week 16 n ¼ 32 n ¼ 28 n ¼ 30 n ¼ 14 n ¼ 12 n ¼ 15
Mean (SD) 2.6 (2.2) 2.4 (1.8) 2.0 (1.6) 3.1 (2.3) 2.7 (2.2) 2.0 (1.7)
P valueb .6064 .2163 .9485 .2552
Stricture
Baselinea n ¼ 32 n ¼ 27 n ¼ 31 n ¼ 14 n ¼ 14 n ¼ 15
Mean (SD) 0.7 (1.0) 0.6 (1.0) 0.3 (0.5) 1.0 (1.2) 0.6 (1.1) 0.3 (0.5)
Week 16 n ¼ 32 n ¼ 27 n ¼ 30 n ¼ 14 n ¼ 12 n ¼ 15
Mean (SD) 0.5 (0.8) 0.4 (0.9) 0.2 (0.4) 0.7 (1.1) 0.7 (1.2) 0.2 (0.4)
P valueb .4043 .2151 .8925 .3689
SD, standard deviation.
aBaseline is deﬁned as the last observed score before the ﬁrst dose of study drug.
bP values comparing RPC4046 180 mg with placebo and RPC4046 360 mg with placebo are based on an analysis of
covariance model with treatment group as the factor and the baseline mean adjusted score as a covariate.
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Supplementary Table 5.Mean Esophageal Eosinophil Count
in the Steroid-refractory Subgroup
Steroid-refractory subjects
Placebo
(n ¼ 16)
RPC4046
180 mg (n ¼ 14)
RPC4046
360 mg (n ¼ 17)
Baselinea n ¼ 16 n ¼ 14 n ¼ 17
Mean (SD) 79.2 (47.1) 146.9 (83.1) 127.5 (78.2)
Week 16 n ¼ 15 n ¼ 12 n ¼ 15
Mean (SD) 101.6 (64.7) 27.5 (35.4) 28.3 (34.8)
P valueb .0001 <.0001
SD, standard deviation.
aBaseline is deﬁned as the last observed mean esophageal
eosinophil count before the ﬁrst dose of study drug.
bP values comparing RPC4046 180 mg with placebo and
RPC4046 360 mg with placebo are based on an analysis of
covariance model with treatment group as a factor and the
baseline mean esophageal eosinophil count as a covariate.
Supplementary Table 6.Exploratory Analyses of Mean
Esophageal Eosinophil Count and
Composite Diary Score in the
Steroid-responsive Subgroup
Steroid-responsive subjects
Placebo
(n ¼ 34)
RPC4046
180 mg
(n ¼ 31)
RPC4046
360 mg
(n ¼ 34)
Mean esophageal
eosinophil count
Baselinea n ¼ 18 n ¼ 17 n ¼ 17
Mean (SD) 104.11 (58.46) 91.75 (64.30) 117.61 (65.24)
Week 16 n ¼ 18 n ¼ 16 n ¼ 15
Mean (SD) 80.78 (41.84) 22.82 (35.59) 22.69 (25.13)
P valueb <.0001 <.0001
Composite
diary score
Baselinec n ¼ 18 n ¼ 12 n ¼ 16
Mean (SD) 26.88 (9.10) 24.48 (11.95) 28.81 (10.95)
Week 16 n ¼ 18 n ¼ 16 n ¼ 17
Mean (SD) 16.07 (17.60) 18.75 (16.73) 13.90 (15.76)
P valued .8541 .5042
SD, standard deviation.
aBaseline is deﬁned as the last observed mean esophageal
eosinophil count before the ﬁrst day of study drug.
bP values comparing RPC4046 180 mg with placebo and
RPC4046 360 mg with placebo are based on an analysis of
covariance model with treatment group and the baseline
mean esophageal count as a covariate.
cBaseline is deﬁned as the composite diary scores in the last
11–14 days during the screening period.
dP values comparing RPC4046 180 mg to placebo and
RPC4046 360 mg to placebo are based on an analysis of
covariance model with treatment group and the baseline
composite diary score as a covariate.
Supplementary Table 4.Stricture Features of Total
Population
Placebo
(n ¼ 34)
RPC4046
180 mg (n ¼ 31)
RPC4046
360 mg (n ¼ 34)
Number (%) of subjects with strictures
Baselinea
None 19/32 (59.4) 18/27 (66.7) 24/33 (72.7)
Present 13/32 (40.6) 9/27 (33.3) 9/33 (27.3)
Week 16
None 20/33 (60.6) 22/28 (78.6) 24/30 (80.0)
Present 13/33 (39.4) 6/28 (21.4) 6/30 (20.0)
Stricture estimated diameter (mm)
Baselinea
None 19/32 (59.4) 18/27 (66.7) 24/33 (72.7)
4–6 0 0 0
7–9 1/32 (3.1) 2/27 (7.4) 1/33 (3.0)
10–12 7/32 (21.9) 3/27 (11.1) 2/33 (6.1)
13–15 4/32 (12.5) 4/27 (14.8) 1/33 (3.0)
16–18 1/32 (3.1) 0 4/33 (12.1)
>18 0 0 1/33 (3.0)
Week 16
None 20/33 (60.6) 22/28 (78.6) 24/30 (80.0)
4–6 0 0 0
7–9 3/33 (9.1) 0 0
10–12 4/33 (12.1) 3/28 (10.7) 3/30 (10.0)
13–15 4/33 (12.1) 3/28 (10.7) 1/30 (3.3)
16–18 2/33 (6.1) 0 1/30 (3.3)
>18 0 0 1/30 (3.3)
aBaseline is deﬁned as the last observed score before the ﬁrst
dose of study drug.
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Supplementary Table 7.Mean Composite Diary Score in the
Steroid-refractory Subgroup
Steroid-refractory subjects
Placebo
(n ¼ 16)
RPC4046
180 mg (n ¼ 14)
RPC4046
360 mg (n ¼ 17)
Baselinea n ¼ 14 n ¼ 14 n ¼ 12
Mean (SD) 32.7 (12.0) 26.9 (14.6) 29.3 (9.4)
Week 16 n ¼ 16 n ¼ 14 n ¼ 15
Mean (SD) 31.0 (18.1) 25.6 (17.8) 16.9 (19.0)
P valueb .8284 .0547
SD, standard deviation.
aBaseline is deﬁned as the composite diary scores in the past
11–14 days during the screening period.
bP values comparing RPC4046 180 mg with placebo and
RPC4046 360 mg with placebo are based on an analysis of
covariance model with treatment group as a factor and the
baseline composite diary score as a covariate.
Supplementary Table 8.Eosinophilic Esophagitis Histology
Grade and Stage Scores (EoEHSS)
in the Steroid-refractory Subgroup
Steroid-refractory subjects
Placebo
(n ¼ 16)
RPC4046
180 mg (n ¼ 14)
RPC4046
360 mg (n ¼ 17)
Mean adjusted
grade score
Baselinea n ¼ 16 n ¼ 14 n ¼ 17
Mean (SD) 42.4 (15.3) 52.1 (14.0) 51.0 (14.1)
Week 16 n ¼ 15 n ¼ 12 n ¼ 15
Mean (SD) 44.0 (14.0) 20.8 (6.7) 21.4 (6.4)
P valueb <.0001 <.0001
Mean adjusted
stage score
Baselinea n ¼ 16 n ¼ 14 n ¼ 17
Mean (SD) 41.2 (11.2) 47.1 (10.9) 46.9 (10.7)
Week 16 n ¼ 15 n ¼ 12 n ¼ 15
Mean (SD) 42.2 (13.4) 22.1 (10.8) 20.0 (12.7)
P valueb <.0001 <.0001
SD, standard deviation.
aBaseline is deﬁned as the last observed score before the ﬁrst
dose of study drug.
bP values comparing RPC4046 180 mg with placebo and
RPC4046 360 mg with placebo are based on an analysis of
covariance model with treatment group as the factor and the
baseline mean adjusted score as a covariate.
Supplementary Table 9.Eosinophilic Esophagitis Activity
Index (EEsAI) in the Steroid-
refractory Subgroup
Steroid-refractory subjects
Placebo
(n ¼ 16)
RPC4046
180 mg (n ¼ 14)
RPC4046
360 mg (n ¼ 17)
Baselinea n ¼ 16 n ¼ 14 n ¼ 17
Mean (SD) 56.8 (16.3) 57.7 (15.1) 59.9 (14.8)
Week 16 n ¼ 16 n ¼ 14 n ¼ 17
Mean (SD) 51.1 (23.2) 38.6 (27.0) 39.1 (31.0)
P valueb .0852 .0393
SD, standard deviation.
aBaseline is deﬁned as the last observed score before the ﬁrst
dose of study drug.
bP values comparing RPC4046 180 mg with placebo and
RPC4046 360 mg with placebo are based on an analysis of
covariance model with treatment group as a factor and the
baseline EEsAI patient-reported outcomes score as a
covariate.
Supplementary Table 10.Treatment-emergent Serious
Adverse Events by Preferred Term
for the Double-blind Treatment
Period
Preferred term
Placebo
(n ¼ 34)
RPC4046
180 mg
(n ¼ 31)
360 mg
(n ¼ 34)
Total serious adverse eventsa 2 0 1
Patients with a serious
adverse event
2 (5.9) 0 1 (2.9)
Umbilical hernia 1 (2.9) 0 0
Appendicitis 1 (2.9) 0 1 (2.9)
Data are number or number (%).
aThe deﬁnition of a serious adverse event is any untoward
medical occurrence that results in death, is life-threatening
(has an immediate risk of death), requires admission to a
hospital or prolongation of existing hospitalization, results in
persistent or signiﬁcant disability or incapacity, or results in a
congenital anomaly or birth defect.
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Supplementary Table 11. Injection Site TEAEs
Placebo
(n ¼ 34)
RPC4046
180 mg
(n ¼ 31)
360 mg
(n ¼ 34)
Number of subjects
experiencing >1 TEAE
6 (17.6) 4 (12.9) 9 (26.5)
Injection site erythema 2 (5.9) 0 3 (8.8)
Injection site hematoma 0 0 2 (5.9)
Injection site pain 3 (8.8) 1 (3.2) 1 (2.9)
Injection site pruritus 1 (2.9) 0 2 (5.9)
Injection site reaction 1 (2.9) 1 (3.2) 1 (2.9)
Injection site bruising 0 0 1 (2.9)
Injection site inﬂammation 0 1 (3.2) 0
Injection site irritation 0 1 (3.2) 0
Injection site mass 0 1 (3.2) 0
Injection site edema 0 1 (3.2) 0
Injection site swelling 0 0 1 (2.9)
Injection site urticaria 0 0 1(2.9)
Data are number (%).
TEAE, treatment-emergent adverse event.
February 2019 RPC4046 EoE Phase 2 Trial 603.e10
